San Diego, CA, United States of America

Yong-Min Yang

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2009.


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yong-Min Yang

Introduction: Yong-Min Yang is a notable inventor based in San Diego, CA. He has made significant contributions to the field of immunology, particularly in the development of vaccines targeting immunoglobulin E-mediated diseases. His innovative work has the potential to improve therapeutic strategies for various allergic conditions.

Latest Patents: Yong-Min Yang holds a patent for "Immunoglobulin E vaccines and methods of use thereof." This invention focuses on the prophylaxis and therapy of immunoglobulin E-mediated disease conditions. The patent discloses methods for identifying peptides that induce a cytotoxic T-lymphocyte response against immunoglobulin E. Furthermore, it presents compositions capable of eliciting a cytotoxic T-lymphocyte response to naturally processed and presented immunoglobulin E peptides, along with methods for their application. He has 1 patent to his name.

Career Highlights: Throughout his career, Yong-Min Yang has demonstrated a commitment to advancing medical science through his research and inventions. His work has been instrumental in exploring new avenues for treating allergic diseases, showcasing his expertise in immunology and vaccine development.

Collaborations: Yong-Min Yang has collaborated with esteemed colleagues in his field, including Swey-Shen Chen and Zhong Yu Chen. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion: Yong-Min Yang's contributions to immunology and vaccine development highlight his role as a significant inventor in the field. His innovative approaches to treating immunoglobulin E-mediated diseases pave the way for future advancements in medical therapies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…